Kyverna Therapeutics, Inc. Common Stock (KYTX) Stock Price

KYTXStock
$8.37+126.22%52W
Market Cap$517.63M
P/E
PEG Ratio
Div yield
Beta2.03

KYTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-6.65%
Price vs S&P 500 (4W)9.91%
VGM Score66.85

KYTX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.68-$0.63+7.28%(+$0.05)
Q4 2025-$0.86-$0.80+6.80%(+$0.06)
Q3 2025-$0.97-$0.85+12.47%(+$0.12)
Q2 2025-$1.04-$0.97+7.15%(+$0.07)

KYTX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
KYTXKyverna Therapeutics, Inc. Common Stock
B$8.37
AMGNAmgen IncCCB$432.42
GILDGilead Sciences IncCBB$145.68
ARGXargenx SE American Depositary SharesDAB$1023.21
MRNAModerna, Inc. Common StockDCA$137.99
RVMDRevolution Medicines, Inc. Common StockFA$207.88
BIIBBiogen Inc. Common StockCDB$218.50
BNTXBioNTech SE American Depositary ShareCCC$102.08
NBIXNeurocrine Biosciences IncCBC$154.06
EXELExelixis IncCBB$54.45
HALOHalozyme Therapeutics, Inc.CBB$105.35

About Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases. Its pipeline includes KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version designed for multiple autoimmune indications.